Bright Minds Biosciences Inc.
DRUG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001827401
No open-market purchases or sales by Bright Minds Biosciences Inc. insiders were filed in the last 90 days; 99 institutions reported holding it in 13F filings for Q2 2026, worth $653.8M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Bright Minds Biosciences Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 0 | 9 | +9 |
| Shares | 0 | 911.1K | +911.1K |
| Value | $0 | $2.93M | +$2.93M |
New holders (9)
Institutions that held Bright Minds Biosciences Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| OrbiMed Advisors LLC | 660,600 | $2.13M | 0.03% |
| Ikarian Capital, LLC | 100,000 | $317.0K | 0.09% |
| AdvisorShares Investments LLC | 95,942 | $304.0K | 0.04% |
| Quattro Financial Advisors LLC | 21,150 | $67.0K | 0.02% |
| Checchi Capital Advisers, LLC | 14,138 | $45.0K | 0.00% |
| Boothbay Fund Management, LLC | 11,040 | $35.0K | 0.00% |
| BlackRock Inc. | 6,169 | $20.0K | 0.00% |
| UBS Group AG | 1,558 | $5.00K | 0.00% |
| Aspire Private Capital, LLC | 500 | $2.00K | 0.00% |
Sold out (0)
Institutions that held Bright Minds Biosciences Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
None.